摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 4,5-O-isopropylidene-3-dehydro-4-epi-shikimate | 97205-16-8

中文名称
——
中文别名
——
英文名称
methyl 4,5-O-isopropylidene-3-dehydro-4-epi-shikimate
英文别名
methyl 4,5-O-isopropylidene-3-oxo-4-epi-shikimate;methyl (3aR,7aR)-2,2-dimethyl-7-oxo-4,7a-dihydro-3aH-1,3-benzodioxole-5-carboxylate
methyl 4,5-O-isopropylidene-3-dehydro-4-epi-shikimate化学式
CAS
97205-16-8
化学式
C11H14O5
mdl
——
分子量
226.229
InChiKey
DDUDKBIBHSVYFY-BDAKNGLRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    61.8
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Catalytic asymmetric epoxidation
    申请人:——
    公开号:US06348608B1
    公开(公告)日:2002-02-19
    A compound and method for producing an enantiomerically enriched epoxide from an olefin using a chiral ketone and an oxidizing agent is disclosed.
    一种化合物及其生产方法被披露,该方法使用手性酮和氧化剂从烯烃生产具有对映体富集的环氧乙烷。
  • Regio- and stereoselective synthesis of the carbocyclic analogue of 3-deoxy-β-D-manno-2-octulopyranosonic acid (β-KDO) from (-)-quinic acid.
    作者:H. Molin、B.G. Pring
    DOI:10.1016/s0040-4039(00)89177-7
    日期:1985.1
    The carbocyclic analogue of β-KDO has been synthesized from (-)-quinic acid.
    β-KDO的碳环类似物是由(-)-奎宁酸合成的。
  • Novel and Efficient Syntheses of (−)-Methyl 4-<i>e</i><i>pi</i>-Shikimate and 4,5-Epoxy-Quinic and -Shikimic Acid Derivatives as Key Precursors to Prepare New Analogues
    作者:Laura Sánchez-Abella、Susana Fernández、Nuria Armesto、Miguel Ferrero、Vicente Gotor
    DOI:10.1021/jo0606249
    日期:2006.7.1
    We have developed simple methods that provide a rapid entry into the synthesis of a series of quinate and shikimate analogues, including (−)-methyl 4-epi-shikimate and the 4,5-epoxy analogues of the parent acids. Epoxy derivatives of quinic and shikimic acids were converted into methyl scyllo-quinate and (+)-methyl 3-epi-shikimate, respectively, by processes involving a regio- and stereoselective epoxide
    我们已经开发出简单的方法,这些方法可快速进入一系列奎宁酸盐和sh草酸盐类似物的合成,包括(-)-4- Epi -shikimate的甲基和母体酸的4,5-环氧类似物。的奎尼和莽草酸环氧衍生物转化成甲基鲨-quinate和(+) - 3-外延分别-shikimate,通过涉及区域选择性和立体选择性环氧化物开环过程。所描述的策略是通过短而高产的反应序列进行的。
  • [EN] ANTIMICROBIAL AGENTS<br/>[FR] AGENTS ANTIMICROBIENS
    申请人:UNIV WARWICK
    公开号:WO2018193273A1
    公开(公告)日:2018-10-25
    The invention provides novel analogues of enacyloxin Ha and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs. Such compounds are effective in the treatment of infections caused by Gram-negative bacteria such as Acinetobacter baumannii. Compounds in accordance with the invention include those of formula (A), and their pharmaceutically acceptable salts, metabolites, isomers (e.g. stereoisomers) and prodrugs: In formula (A): X is 0 or NRx (where R* is either H or C1-3 alkyl, e.g. CH3); R1 is a 5- or 6-membered, saturated or unsaturated, carbocyclic ring optionally substituted by one or more substituents, or R1 is an optionally substituted straight-chained or branched C-1-6 alkyl group (e.g. C1-3 alkyl group); R2 is H, F, CI, Br, I or CH3; R3 is H or OH; R8 is a straight-chained or branched C1-8 alkyl group (e.g. a C1-6 aikyl group); Y is one of the following groups: (wherein each * denotes the point of attachment of the group to the remainder of the molecule; R9 is H, F, CI, Br or I; R4 and R5 are independently selected from H and OH, or R4 and R5 together are =0, preferably R4 is H and R5 is OH; R6 is H, F, CI, Br, I or CH3; R7 is H and R7' is OH, or R7 and R7' together are =0, preferably R7 is H and R7' is OH); and each— independently represents an optional bond (i.e. each of C2-C3, C4-C5, C6-C7, C8-C9 and C10-C11 are independently either C-C (single) or C=C (double) bonds).
    这项发明提供了恩氨环素Ha的新型类似物及其药学上可接受的盐、代谢物、同分异构体(例如立体异构体)和前药。这些化合物在治疗由革兰氏阴性细菌引起的感染方面具有有效性,如包括鲍曼不动杆菌在内。符合该发明的化合物包括式(A)的化合物及其药学上可接受的盐、代谢物、同分异构体(例如立体异构体)和前药:在式(A)中:X为0或NRx(其中R*为H或C1-3烷基,例如CH3);R1为一个5-或6-成员的、饱和或不饱和的、碳环,可选择地由一个或多个取代基取代,或R1为一个可选择地取代的直链或支链C-1-6烷基基团(例如C1-3烷基基团);R2为H、F、Cl、Br、I或CH3;R3为H或OH;R8为一个直链或支链C1-8烷基基团(例如C1-6烷基基团);Y为以下各组中的一个:(其中每个*表示该组与分子其余部分的连接点;R9为H、F、Cl、Br或I;R4和R5分别独立选择自H和OH,或R4和R5一起为=0,优选R4为H且R5为OH;R6为H、F、Cl、Br、I或CH3;R7为H且R7'为OH,或R7和R7'一起为=0,优选R7为H且R7'为OH);每个—独立表示一个可选键(即C2-C3、C4-C5、C6-C7、C8-C9和C10-C11中的每一个独立地是C-C(单)或C=C(双)键)。
  • [EN] COMPOUNDS AND METHODS FOR TREATMENT OF INFLUENZA<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT DU VIRUS INFLUENZA
    申请人:UNIV FRASER SIMON
    公开号:WO2010075636A1
    公开(公告)日:2010-07-08
    The present invention provides in part a compound of Formula (I) or a pharmaceutically- acceptable salt or stereoisomer thereof: where R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea group, a thiourea group, an amidine group, and N3; and R2 is selected from the group consisting of H, Me, Et and an amino acid, and methods and uses thereof.
    本发明部分提供了一种化合物,其化学式为(I)或其药用盐或立体异构体:其中R1选自以下组:取代三唑基团、胍基团、脲基团、硫脲基团、酰胺基团和N3;R2选自以下组:H、Me、Et和氨基酸,以及其方法和用途。
查看更多